ArticleOncogene2006
Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Transcription Factor MYB as Therapeutic Target: Current Developments.International journal of molecular sciences · 2024Review
- Article
- Development and Characterization of MYB-NFIB Fusion Expression in Adenoid Cystic Carcinoma.Cancers · 2022Article
- Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.Molecules (Basel, Switzerland) · 2022Review
- MYB oncoproteins: emerging players and potential therapeutic targets in human cancer.Oncogenesis · 2021Review
- Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma.Leukemia · 2020Article
- Article
- Article
- MYB promotes the growth and metastasis of salivary adenoid cystic carcinoma.International journal of oncology · 2019Article
- Editorial: Targeting MYB Oncogene Expression in Adenoid Cystic Carcinoma.Journal of the National Cancer Institute · 2017Article
- Mutations in THAP11 cause an inborn error of cobalamin metabolism and developmental abnormalities.Human molecular genetics · 2017Article
- Article
- Optimized approach for Ion Proton RNA sequencing reveals details of RNA splicing and editing features of the transcriptome.PloS one · 2017Article
- Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma.Cancer discovery · 2016Article
- A compendium of monocyte transcriptome datasets to foster biomedical knowledge discovery.F1000Research · 2016Article
- A curated compendium of monocyte transcriptome datasets of relevance to human monocyte immunobiology research.F1000Research · 2016Article
- The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target.Molecular cancer therapeutics · 2015Article
- Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis.Cancers · 2014Review
- Article
- Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I.Leukemia · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The v-Myb oncoprotein encoded by Avian Myeloblastosis Virus is highly oncogenic, induces leukemias in chickens and mice and transforms immature hematopoietic cells in vitro. The v-Myb protein is a mutated and truncated version of c-Myb, a DNA-binding transcription factor expressed in many cell types that is essential for normal hematopoiesis. Previous studies suggested that two types of differences, DNA binding domain mutations and the deletion of a C-terminal negative regulatory domain were important for increasing the transforming activity of v-Myb. Here, we combined structure-function studies of the v-Myb and c-Myb proteins with unbiased microarray-based transcription assays to compare the transcriptional specificities of the two proteins. In human cells, the v-Myb and c-Myb proteins displayed strikingly different activities and regulated overlapping, but largely distinct sets of target genes. Each type of mutation that distinguished v-Myb from c-Myb, including the N- and C-terminal deletions, DNA binding domain changes and mutations in the transcriptional activation domain, affected different sets of target genes and contributed to the different activities of c-Myb and v-Myb. The results suggest that v-Myb is not just a de-repressed version of c-Myb. Instead, it is a distinct transcriptional regulator with a unique set of activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.